Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.2MCash on Hand
6mo Cash Runway
Follow PULM by emailGet an email when PULM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PULM, unsubscribe in one click. Privacy
📣 What PULM Says Is Next
in 2026 · “Cipla has continued clinical development outside the United States, and completed their Phase 2 study in India, published positive results and has been approved by India’s Central Drug Standard Control Organization to proceed with a Phase 3 clinical trial, which Cipla currently expects to commence in 2026.”
Company press release, Nov 17, 2026 · SEC filing
in November 2026 · “The proposed Merger is currently anticipated to close in November 2026, subject to Nasdaq’s approval of the listing of the shares of the Company’s common stock to be issued in connection with the Merger, the completion of the reverse stock split approved by the Company’s stockholders on October 26, 2026, and other customary closing conditions.”
Company press release, Nov 17, 2026 · SEC filing
in 2026 · “Cipla has continued clinical development outside the United States, and in 2025 completed their Phase 2 study in India, published positive results and has been approved by India’s Central Drug Standard Control Organization to proceed with a Phase 3 clinical trial, which Cipla currently expects to commence in 2026.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Earnings Pulmatrix reported Q3 2026 results with cash and cash equivalents of $1.4 million at September 30, 2026, down from $4.1 million at year-end 2025. It expects its cash to fund operations through the anticipated Eos SENOLYTIX merger closing, now expected by year-end. Form 8-K · SEC filing · Press release
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 27, 2026 ·
Shareholder vote Shareholders approved the Eos merger share issuance, a reverse split of 1 new share for every 2 to 10 shares at the board's ratio, and an increase in authorized common stock from 200,000,000 to 250,000,000 shares. Votes were held at a special meeting on October 26, 2026. Form 8-K · SEC filing
Oct 26, 2026 ·
Financing Pulmatrix is registering resale of up to 491,607 common shares, including 37,061 dividend shares, for a selling stockholder holding Series B preferred stock bought in an April 2026 private placement. Conversion price is $2.20, and the shares equal about 13% of outstanding common stock. Form 424B3 · SEC filing
Sep 25, 2026 ·
Shareholder vote Pulmatrix filed a proxy and prospectus for a special meeting on October 16, 2026, to vote on its merger with Eos SENOLYTIX, which would issue 75,245,366 shares of common stock. Stockholders also vote on a reverse split of 2 to 10 shares into 1, and on increasing authorized shares from 200,000,000 to 250,000,000. Form 424B3 · SEC filing
Aug 13, 2026 ·
Earnings Pulmatrix reported Q2 2026 results: G&A fell to $1.0 million from $1.5 million, cash was $2.2 million at June 30, 2026, and an S-4 was filed for the Eos SENOLYTIX merger, expected to close in Q3 2026. All clinical development is on hold while it seeks to license or monetize its assets. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2022 · Phase 1 · Results Expected · A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults Registry primary completion date, not a results date
Dec 2021 · Phase 1 · Results Expected · A Phase 1b Study of PUR1800 in Patients With COPD Registry primary completion date, not a results date
Jun 2018 · Phase 1 · Results Expected · Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma Registry primary completion date, not a results date
Mar 2016 · Phase 1 · Results Expected · A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects Registry primary completion date, not a results date
Aug 2014 · Phase 1 · Results Expected · 21 Day Cumulative Skin Irritation of RUT058-60 Registry primary completion date, not a results date
Dec 2013 · Phase 1 · Results Expected · A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not PULM's own candidates): Hypochlorous Acid, Itraconazole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PULM holds $2.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.1M/quarter from operations,
an estimated runway of 6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 4 months +40
ATM program on file since May 2024 +15
Shelf registration (S-3, May 2024) +10
Going-concern doubt in the latest 10-Q +15Management believes that, given the Company’s current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about its ability to continue as a going concern through the date that is one year from the date that these financial statements are…10-Q, Nov 2026
Share count 3,652,285 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PULM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PULM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.